AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06352307 — intervention group
Intervention type: OTHER
Intervention: Diagnosis of ACM
Description: Definite ACM diagnosis is based on the consensus-based 2010 Task Force Criteria, which include major and minor criteria in six categories (depolarization and repolarization abnormalities, arrhythmia, imaging, histology, and family history/genetics). Among these, repolarization abnormalities (T-wave inversion in the precordial leads) constitute the most commonly observed, followed by frequent premature ventricular complex. With regards to imaging techniques, both the presence of wall motion abnormalities and an abnormal ventricular volume or function are required for fulfilment. Definite ACM consists of two major criteria or one major and two minor criteria or four minor criteria from different categories. Borderline ACM consists of one major and one minor criterion or three minor criteria from different categories.
Study NCT05726474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined exercise
Description: Patients will exercise for 40 minutes three times a week on an ergometric bicycle at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without ergometer at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without shortness of breathing difficulty. In addition, strength training will be performed (bench press, leg press, leg curl, leg machine, bench press, leg press, leg curl, leg curl, leg machine). leg curls, leg curls, rowing machine, triceps dips, pectoral pull-ups) twice a week. week. Strength training will be performed with 15 repetitions per exercise and per session, with a corresponding workload of 15 repetitions. session, with a workload corresponding to 60% to 65% of the 1-repetition maximum (1RM) measured at (1RM) measured at the beginning and at the end of the intervention.
Study NCT05726474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High interval training
Description: Patients will perform three training sessions per week. Each training session begins with a 10-minute warm-up at moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, no shortness of breath) before cycling, four 4-minute intervals at high intensity (corresponding to 85-90% of VO2max, 90-95% of HRmax, 15-17 on the Borg scale, shortness of breath). Each interval will be separated by 3 minutes of active pauses, with a HRmax of 50-70%. The training session will end with 3 minutes of cool down at moderate intensity (corresponding to 50-60%). moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without difficulty). Borg scale, no shortness of breath). The total exercise time will be 40 minutes for the HIIT group.
Study NCT05578378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine combine with cytarabine will be intravenous on days 1-5; G-CSF will be hypodermic injection on day0-5,4 weeks per cycle.
Study NCT05578378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Control arm~Patients in the control arm received the investigator's choice of one of the following three regimens:~FLAG:Fludarabine(30mg/m2)should be intravenous use on day 1-5, granulocyte colony-stimulating factor will be hypodermic injection using 300 μg per day on days 0-5,cytarabine (1.5 mg/m2) every 12 hours, intravenous infusion on day1-5,4 weeks per cycle.~a high-dose cytosine arabinoside-based regimen; a high-dose methotrexate-based regimen
Study NCT05217407 — intervention group
Intervention type: OTHER
Intervention: Genomic sequence
Description: Genomic sequence
Study NCT05926011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RGn600
Description: RGn600 with a 10 Hz-pulsed wave mode light emission
Study NCT05926011 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RGn600 Sham
Description: RGn600 inactivated
Study NCT06203028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cyberbullying Awareness Training
Description: The 'Cyberbullying Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours. The training program will be implemented in line with the headings 'Definition of cyberbullying, Cyberbullying tools and practices, Case studies on cyberbullying, Causes of cyberbullying, Academic, social, psychological and physical effects of cyberbullying, Coping strategies with cyberbullying'.
Study NCT05015686 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd
Description: live varicella-zoster virus in trehalose,human serum albumin,sodium glutamate,sucrose,glucose,carbamide,arginine and injection water per injection
Study NCT05015686 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride and distilled water
Study NCT04874831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: domatinostat in combination with avelumab
Description: domatinostat tablets and avelumab infusion
Study NCT02546739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19-CAR
Description: Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
Study NCT05182034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(low dose)
Description: A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
Study NCT05182034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(mid dose)
Description: A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
Study NCT05182034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Group Sodium chloride
Description: A single knee administration of Sodium chloride
Study NCT05188560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation therapy
Description: Subject is asked to observe videos with motor contents
Study NCT05188560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor imagery
Description: mental simulation of a motor task
Study NCT05752825 — intervention group
Intervention type: RADIATION
Intervention: HR-pQCT
Description: HR-pQCT is a 3-dimensional imaging modality that can be applied to bone and joints in vivo, in order to non-invasively assess the quantity and quality of trabecular and cortical bone compartments separately. HR-pQCT will be applied to peripheral skeletal sites, namely the distal radius and tibia, where image slices equivalent to 9 mm of bone will be acquired. From this, parameters such as volumetric bone mineral density (vBMD), cortical density, cortical porosity, trabecular density, trabecular thickness, trabecular spacing and others will be calculated using specialized software. In the same scanning session, images of the wrist and ankle joints will be produced and analyzed for features of arthrosis, such as erosions, osteophytosis and others.
Study NCT05752825 — intervention group
Intervention type: RADIATION
Intervention: DXA scan
Description: Through DXA scans, we will obtain information regarding body composition, hip and spine bone mineral density, as well as examine any previous vertebral fractures using vertebral fracture assessment (VFA). VFA is a function of DXA scanners which allows for visualization of thoracic and lumbar vertebrae (usually T4-L4) in order to detect vertebral fractures34. Vertebral fractures can then be classified as either mild, moderate or severe using the method described by Genant et al35.
Study NCT05752825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bone microindentation
Description: Using the OsteoProbe®, we will by microindentation measure the bone material strength index (BMSi), an in vivo surrogate measure of the fracture resistance of the cortical bone in the tibia. The participant is placed in a supine position with the examined leg rotated slightly outward. After identifying the site of interest, located midway between the medial tibial plateau and the medial malleolus, disinfectant is applied to the skin of the tibia being examined. Finally, under local anesthesia and fully sterile conditions, a test probe is inserted through the skin and onto the midshaft of the tibia, and the fracture resistance of the bone tissue is measured.
Study NCT05752825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hand grip and leg extension strength
Description: Hand grip strength will be assessed using a digital hand dynamometer as a measure of peripheral muscle strength. Leg extensor strength will be examined using the peak torque measured by an isometric dynamometer mounted on a fixed chair. 3 attempts will be given for each method, and the maximum value recorded.
Study NCT05752825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Timed up-and-go test
Description: The TUG test is a functional test frequently used to assess balance in older individuals and is performed by measuring the time it takes for an individual to go from sitting to standing position, walk 3 meters, turn around and return to sitting position. A TUG score of >13,5 seconds is associated with an increased risk of falls.
Study NCT05752825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stabilometry
Description: Postural control will be assessed by means of a force platform that registers Center of Pressure (CoP) as a measure of postural stability. Measurements are performed under a variety of conditions, including eyes open/closed and on different surfaces. From the CoP measurements, parameters such as CoP range and CoP velocity in both antero-posterior and medial-lateral directions will be calculated using specialized software.
Study NCT05752825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve conduction test
Description: To fully examine all components of balance, nerve conduction will be tested using a handheld device called NC-stat DPN-Check in order to assess any peripheral neuropathy.
Study NCT05234203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HTB Rejuvenate
Description: 90 days of BID dosing of 2 capsules of HTB Rejuvenate
Study NCT05898230 — intervention group
Intervention type: DEVICE
Intervention: Mitral Valve Replacement
Description: Mitral Valve Replacement with Carbomedics OptiForm Mitral Heart Valve
Study NCT05009940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graduated compression stockings
Description: Both GraduSOX and Sigvaris are graduated compression stockings. These exert the greatest degree of of compression at the ankle, and the level of compression gradually decreases up the garment.
Study NCT05752825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual acuity test
Description: Visual acuity will be tested using an automated refractometer (KR-800S Auto-kerato-refractometer, Topcon Healthcare, The Netherlands).
Study NCT04871555 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: structural imaging
Study NCT05197179 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion
Study NCT05197179 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FB2001 placebo
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion
Study NCT06358105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulator-based training
Description: A two-day training program will be performed before starting their cath lab period as interventional cardiology fellows
Study NCT06358105 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard training
Description: Standard master-apprentice training interventional cardiology fellows' program during their cath lab period
Study NCT06637592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calcaneal taping
Description: Calcaneal taping is a method employed to offer assistance and relieve discomfort in the heel and ankle area. Start with a clean surface and apply first tape from lateral malleolus, pulling calcaneus in medial direction and attach to medial malleolus. Apply two more tapes in the same manner going distally. Apply an anchor tape at back of heel.
Study NCT06637592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Windlass taping
Description: Begin by anchoring the tape just above the ball of the foot (metatarsal heads). Tear or cut a strip of tape, approximately 2-3 inches long, and place it horizontally around the foot, securing the starting point. Pull the tape diagonally across the bottom of the foot, aiming to support the arch. The tape should be applied with moderate tension to provide support without causing discomfort. While keeping tension on the tape, extend the big toe (great toe) upward. As the toe extends, the tape should tighten, activating the windlass mechanism and providing additional arch support.
Study NCT04696939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab intravenous infusion was administered at a dose of 1200mg on Day 1 of each 21-day cycle.
Study NCT04696939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion was administered at a dose of 75mg/m\^2 on Day 1 of each 21-day cycle.
Study NCT04696939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin intravenous infusion was administered at a dose of 75mg/m\^2 on Day 1 of each 21-day cycle.
Study NCT04149210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% Oph Susp
Description: fluorometholone 0.1% one drop twice daily for four weeks, beginning with one drop just before trachomatous trichiasis surgery on the upper lid.
Study NCT04149210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Tears
Description: Artificial tears (placebo) given one drop twice daily for four weeks, beginning with one drop just prior to trachomatous trichiasis surgery on the upper lid.
Study NCT04696939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Day 1 of every 3-day cycle.
Study NCT04696939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Day 1 of every 3-day cycle.
Study NCT04981431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Oral administration
Study NCT04981431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration
Study NCT05514678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy
Description: CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and 10 min. 45 minutes in total, including the ending. in progress.
Study NCT05082948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suture fixation of stent
Description: Esophageal stent will be placed in the standard of care fashion by the endoscopists using standard gastroscopes. Covered self-expanding metal stent will be placed as per endoscopist preference. After esophageal stent placement, endoscopic suturing will be performed in cases of patients randomized to suture fixation.
Study NCT05082948 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non suture
Description: Standard placement of stent without suture fixation
Study NCT03803657 — intervention group
Intervention type: DEVICE
Intervention: Monitoring of energy expenditure
Description: Continuous monitoring of energy expenditure.
Study NCT05735379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deprescribing anticholinergic and sedative mediications
Description: Deprescribing plan targeting a reduction in Drug Burden Index score of ≥ 0.5
Study NCT06318572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Description: Patients will have 3 visits during the 7 weeks study length. On day -7 a first visit will be made verifying that inclusion criteria are met, the informed consent will be obtained and a rectal sensitivity test will be performed. A symptom questionnaire will be delivered to the patient for daily assessment of gastrointestinal symptoms.~On day 0, a stool sample will be collected and the symptom questionnaire will be reviewed to confirm inclusion criteria. Patients will begin the program of psychological intervention. A first, session of psychoeducation will be performed, and thereafter sessions of psychotherapy will be performed at home during 6 weeks.~At the end of treatment a last visit will be performed, collecting the symptoms scored during the last 7 days. A new stool sample will be collected and a rectal sensitivity study will be performed.~Severity of symptom questionnaire will be filled at the beginning, after 3 weeks, at the end of the treatment, at 3 months and at 6 months.
Study NCT06318572 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will have 3 visits during the 7 weeks study length. On day -7 a first visit will be made verifying that inclusion criteria are met, the informed consent will be obtained and a rectal sensitivity test will be performed. A symptom questionnaire will be delivered to the patient for daily assessment of gastrointestinal symptoms.~On day 0, a stool sample will be collected and the symptom questionnaire will be reviewed to confirm inclusion criteria. Patients will be instructed to take a capsule containing 0.5 g during 6 weeks.~At the end of treatment a last visit will be performed, collecting the symptoms scored during the last 7 days, A new stool sample will be collected and a rectal sensitivity study will be performed.~Severity of symptom questionnaire will be filled at the beginning, after 3 weeks, at the end of the treatment, at 3 months and at 6 months.
Study NCT05470465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Oxycodone
Description: Participants will receive placebo on days 1-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
Study NCT05470465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine and Oxycodone
Description: Participants will receive 40 mg paroxetine (2 x 20 mg tablets) on days 1-6 and 60 mg paroxetine (3 x 20 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
Study NCT05470465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram and Oxycodone
Description: Participants will receive 20 mg escitalopram (2 x 10 mg tablets) on days 1-6 and 30 mg escitalopram (3 x 10 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
Study NCT05185960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALLSWEET®
Description: ALLSWEET®, is a non-GMO certified allulose developed by the study sponsor. It will be diluted in water.
Study NCT05185960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALLSWEET® and sucrose
Description: ALLSWEET®, is a non-GMO certified allulose developed by the study sponsor. It will be added to sucrose (table sugar) and diluted in water.
Study NCT05185960 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: Table sugar. It will be consumed by diluting it in water.
Study NCT05315518 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: single-shade universal resin composite (omnichroma) with blocker( omnichroma blocker)
Description: (OMNICHROMA BLOCKER) is indicated for preventing shade-matching interference in Class IV restorations, Masking dark dentition and dentin. In cases where there is a lack of tooth structure to bond to, (BLOCKER) works as a supplementary product to provide a lingual wall to the restoration, prevent shade-match obstruction and mask staining.
Study NCT05315518 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: single-shade universal resin composite (omnichroma) with blocker( omnichroma blocker)
Description: (OMNICHROMA BLOCKER) is indicated for preventing shade-matching interference in Class IV restorations, Masking dark dentition and dentin. In cases where there is a lack of tooth structure to bond to, (BLOCKER) works as a supplementary product to provide a lingual wall to the restoration, prevent shade-match obstruction and mask staining.
Study NCT05825937 — intervention group
Intervention type: DEVICE
Intervention: ClearSight System
Description: Patients having either elective cardiac surgery or elective neurointerventional surgery will have blood pressure monitored by the ClearSight device, along with the standard of care radial arterial line, throughout their surgery. The arterial line will be placed on the radial artery contralateral to the upper arm blood pressure cuff. The ClearSight device will then be placed on the third finger of the hand ipsilateral to the radial arterial line.
Study NCT04979169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: A series of theory-informed text messages encouraging them to contact their primary care provider and the UR LCS Program's Patient Navigator to coordinate screening, along with contact information to do so.
Study NCT04315337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Kitchen Training
Description: VR Training will include repeated practice of a single, everyday task in a non-immersive VR context (e.g., VR Breakfast) using a laptop with a touch-screen interface for four days over the course of one week.
Study NCT06490328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKF-MA102
Description: Administered twice at 12-week intervals